Considering that knockdown by PMP22 mRNA-targeting treatment correlates with phenotypic improvement in CMT1A animal models (19), quantitative measurements are important for estimating the disease state and its change by therapeutic intervention in CMT1A. Here, PMP22 is linked to Charcot-Marie-Tooth disease type 1A.